Search This Blog

Thursday, March 13, 2025

ImmunoPrecise teases $10M ADC, bispecific collab with major biotech

 ImmunoPrecise Antibodies has secured a collaboration with an undisclosed “leading biotech” to discover new antibody-drug conjugates and bispecific antibodies to treat cancer.

The agreement will harness ImmunoPrecise’s multi-omics artificial-intelligence-driven modeling and discovery platform as well as its B-cell select technology to discover and preclinically develop “multiple antibody-based therapeutics, with a focus on developing highly selective and effective cancer treatments,” according to a March 13 release.

The collaboration will last 18 to 24 months and have an initial value of $8 million, the biotech said, with the potential to expand to $10 million. The aim will be to integrate AI to improve the discovery process.

“This collaboration aims to streamline the path from target discovery to preclinical candidate selection, marking a significant step toward advancing next-generation biologics for cancer treatment,” ImmunoPrecise explained.

While not disclosing its new partner, today’s release described it as a “leading biotechnology company with multi-billion-dollar market capitalization.” Austin, Texas-based ImmunoPrecise has previously secured collaborations with the likes of BioNTech.

“This partnership underscores the power of combining AI-driven discovery with advanced antibody engineering,” ImmunoPrecise’s CEO Jennifer Bath, Ph.D., said in the release.

“With the purchase order secured and work already underway, we are actively leveraging our proprietary B-cell Select platform and LENS technology to accelerate the development of highly targeted cancer therapeutics,” Bath added. “This collaboration highlights IPA’s role in shaping the future of next-generation biologics with data-driven precision and efficiency.”

ADCs have been one of the hottest spaces for dealmaking in recent years, with the likes of AstraZenecaRocheMerck & Co. and Ipsen all posting billion-dollar-plus biobucks pacts.

https://www.fiercebiotech.com/biotech/immunoprecise-teases-10m-adc-bispecific-collab-major-biotech

PDS FDA OKs IND Application for Combo to Treat Metastatic Colorectal Cancer

 Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer Institute

Second Versamune® platform candidate targets MUC1-positive solid tumors

U.S. Patent #12,201,685 covering methods of using combinations of the Versamune® platform and various immunocytokines, including PDS01ADC recently issued

https://www.globenewswire.com/news-release/2025/03/13/3042134/37149/en/PDS-Biotech-Announces-FDA-Clearance-of-IND-Application-for-Combination-of-Versamune-MUC1-and-PDS01ADC-to-Treat-Metastatic-Colorectal-Cancer.html

Novo Nordisk stock rebounds as Kepler upgrades

 Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year.

https://seekingalpha.com/news/4420359-novo-nordisk-rebounds-kepler-upgrades-ozempic-maker

Trump Family Reportedly Holds Deal Talks With Binance

 Representatives of President Trump's family have reportedly been discussing acquiring a stake in the US arm of crypto exchange Binance as the former Coinbase competitor (banned in the US in 2019) plots its re-entry into the world's largest and most pro-crypto economy. This also comes as Binance founder Changpeng Zhao (CZ) pursues a presidential pardon after pleading guilty to violating US anti-money-laundering laws in 2023.

The Wall Street Journal, citing sources familiar with the matter, reports that Trump family members and associates have been discussing with Binance about acquiring a stake in its US arm through World Liberty Financial, a cryptocurrency venture backed by the Trumps.

Sources continued that Trump's longtime friend, Steve Witkoff, now his top negotiator in the Ukraine War and the Middle East, has also been involved in the talks for a deal. 

Binance, the world's largest cryptocurrency exchange, has faced regulatory challenges in the US. In 2019, due to regulatory threats, Binance ceased its primary operations in the US. Officials claimed the exchange facilitated transactions for Hamas and Islamic State and violated AML laws. 

In 2023, Binance paid $4.3 billion to settle the allegations with the US government. As part of the settlement, CZ was required to step down as Binance's chief executive but remains a majority shareholder. CZ served four months in prison for violating AML laws and was released about a month before the US presidential elections last fall. 

WSJ noted, "For the Trump family, a stake in Binance.US would give them the opportunity to participate in the potential revival of a one-time competitor to Coinbase in the U.S. crypto trading market, which is thriving as the administration rolls back regulatory threats that limited its growth." 

It is unclear what type of deal Trump's family would make with Binance or whether it would be contingent on a pardon. CZ and Binance have been eyeing the legal playbook used by the Tron blockchain.  

WSJ added more color on this:

Binance executives saw a potential legal playbook in the saga of Justin Sun, a China-born crypto entrepreneur who invested in a Trump crypto venture last fall as he faced civil charges from the Securities and Exchange Commission, according to a person familiar with the discussions.

Sun, founder of the Tron blockchain, had invested $30 million in November in World Liberty Financial, the Trump-backed crypto venture, becoming its largest investor. Last month, the SEC asked a court to pause its fraud lawsuit against Sun and three of his businesses.

After Sun's investment, Binance executives internally debated following the same route: a cash infusion into World Liberty Financial in exchange for a pardon for Zhao, the person familiar with the discussions said.

If finalized, the deal could revive an old competitor to Coinbase in the cryptocurrency exchange market, as the most pro-crypto president rolls back regulations in the space. A pardon for CZ could pave the way for Binance's return to the US market.

Binance Coin jumped as much as 6% on the WSJ report. Gains were quickly erased about an hour after the release. 

CZ will probably follow the Tron blockchain playbook... 

https://www.zerohedge.com/crypto/trump-family-reportedly-holds-deal-talks-binance

Rabobank: "There's Growing Recognition Trump Is Serious About Radically Reshaping The US"

 By Michael Every of Rabobank

Shock Therapy

Markets were thrilled US inflation was lower than expected headline and core. Just don’t focus on the fact that Europe and Canada raised counter-tariffs on the US; and that Europe’s are up to 50% and aimed at Republican not Democrat states’ products, upping the ante hugely

USTR Greer has already stated: "For years, the EU has opposed US efforts to reindustrialize. The EU has rejected attempts under successive US administrations to cooperate effectively on dealing with global excess capacity on steel, aluminium, and other sectors, employing measures that are too little and too late. If the EU acted as quickly to address global excess capacity as it does to punish the US, we likely would be in a different situation today. The EU’s punitive action completely disregards the national security imperatives of the US – and indeed international security – and is yet another indicator that the EU’s trade and economic policies are out of step with reality."

President Trump has said, “We’ll win that financial battle.” Yet it’s not just financial: Europe is begging for US defense guarantees and needs US LNG as well as Fed swap lines.

Canadian PM-designate Carney says he’s ready to negotiate the USMCA if there’s "respect for Canadian sovereignty". However, statecraft logic dictates the US will want Canada to match whatever external tariffs it sets on China, in which case true sovereignty cannot be retained. Ontario’s Premier Ford will meet with US Commerce Secretary Lutnick today, and we will see if the result is a schmooze, kvetch, or plotz-fest. The BOC cut 25bps to 2.75% as expected yesterday, which was a snooze-fest compared to the geopolitical backdrop. Indeed, as lines on maps blur, arguments are made for Canada to move closer to the EU: it speaks French, has resources Europe needs, and the EU offers it a huge new market. However, Greenland could be literally in the way, as yesterday’s election tipped it closer towards independence, if not the most pro-US party wanting it. Moreover, Canada is adjacent to Russia and areas China is interested in yet spends little on defence even by EU standards; and the US will always border its key economic centers.

Mexico has yet to raise counter-tariffs, waiting until 2 April. Whether this is ‘Fortress North America’ plan, or a wait-and-hope approach remains to be seen.  

The UK hasn’t raised tariffs yet either and will be “negotiating an economic deal which covers and will include tariffs if we succeed,” while “[keeping] all options on the table.” If it were to get a US carve-out, that would point to a statecraft framework of splitting the UK from Europe.

Meanwhile, there’s growing recognition Trump is serious about radically reshaping the US. The Wall Street Journal asks if he is taking a “liquidationist approach”. The Financial Times underlines he sees the need for shock therapy to remake the US to make things again and argues a recession won’t stop him. Indeed, the more one hears ‘Main Street not Wall Street’, ‘national security’, ‘long term, not next quarter’, and ‘don’t focus on stocks’, the more it echoes ‘Common Prosperity’. After all, for a decade I’ve argued that neoliberalism would move closer to mercantilism to resist it. Ironically, however, the markets who didn’t see that China’s Common Prosperity was politically logical before it started, then called it “regulatory reforms”, and took years to finally bewail, “China is uninvestable,” are now floating a pivot from US to Chinese assets.

Regardless, all this market volatility helps cap US 10-year yields, now a White House focus: and how low do stocks have to go before the Fed does what it always does right after telling us that isn’t its role, and it won’t? One wonders, especially as stocks might then go right back up.

Meanwhile Europe’s reflationary rearmament --VW says it may make things for the German army (again)-- is already running into regulatory and supply-side bottlenecks which will only get worse – more so with a trade war with the US, or with a de-risking from it. Indeed, economic history says assuming the EU can rearm on a free market, big-profits basis without unleashing inflation is likely to be wrong. Such issues are explored in our latest global strategy special report, ‘EU economic statecraft update: it’s for real; and for realpolitik’. The conclusion is the EU needs transformational change to achieve its very grand strategy goals.

Of course, that doesn’t mean there won’t be some pampering for markets:

  • EPA head Zeldin just offered “the largest deregulatory announcement in US history”, and tax cuts are floated for everything but foreign production, i.e., tariffs. Of course, that’s as Senate Democrats look to block the House government financing bill that maintains spending at Biden levels to protest DOGE cuts to government spending, threatening a government shutdown of the sort that DOGE could only dream of.
  • China is trying to show it’s all about the private sector again; and yet it’s also saying that it will double down on its over-supply export-led model that leaves firms struggling to make profits in some cases – and to what US, EU, and global response?
  • The EU is also promising a bonfire of the vanities paperwork.

That’s confusing enough a backdrop: but add geopolitics.

The US, having restarted military aid and intel sharing with Ukraine, is now threatening to devastate Russia’s economy if they won’t play ball on peace. Wasn’t that the gameplan from February 2022 up until recently, and how did that work out so far?

Iran has seemingly rejected the US offer of nuclear talks, which may only leave the hard way. And emphasis on the word ‘hard’ there for all involved – and those not involved, like Europe. If the EU thinks Ukraine is all it has to worry about just because it can’t focus on more than one geopolitical problem at once, then it’s sadly wrong.

Indeed, Russia, China, and Iran will tomorrow hold a joint high-level meeting in Beijing to discuss Iran's nuclear program and US threats. There we may also see if the US Noxin (reverse Nixon) geostrategy has any legs or not. Frankly, it would be a shock if it did - because try saying Noxin without saying No, and Xi is right in the middle of it.

However, understand that if that US strategy doesn’t pan out then hard choices could need to be made very quickly. For just one example, the US could have to decide what to do in the Middle East, or to let Israel decide and just lend it a hand; it could have to focus everything else on Asia ASAP; and Europe could find itself rapidly handed the keys and told to look after the continent as best it can while Russia and Iran and China cooperate even more closely. Obviously, the political-economy and market transformations implied in some such scenarios eclipse what has been seen --or, in Europe, promised-- so far.

That may sound shocking, but it should be. It’s not a forecast, but it’s a distinct fat tail risk. And, frankly, one vastly more important than the backwards-looking US CPI figure yesterday.

https://www.zerohedge.com/markets/rabobank-theres-growing-recognition-trump-serious-about-radically-reshaping-us

Aveanna strong Q4 results and upbeat 2025

 Shares of Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH) surged 35% following the announcement of its fourth quarter and full year 2024 financial results, which exceeded analyst expectations and provided a positive outlook for 2025.

The company reported a fourth-quarter earnings per share (EPS) of $0.05, which was $0.05 better than the analyst estimate of $0.00. Revenue for the quarter was $519.9 million, surpassing the consensus estimate of $499.07 million and marking an 8.6% increase compared to the same quarter last year. The positive results were driven by substantial growth across its segments, particularly in Private Duty Services.

For the full year 2025, Aveanna Healthcare anticipates revenues to be between $2.1 and $2.12 billion, aligning closely with the consensus estimate of $2.11 billion. The company’s Adjusted EBITDA for the fourth quarter of 2024 showed a significant increase of 42.8% compared to the fourth quarter of 2023, reaching $55.2 million.

Aveanna’s revenue for the fiscal year ended December 28, 2024, was reported at $2,024.5 million, a 6.8% increase from the previous year. The company also managed to turn around its net income position, reporting $29.2 million in net income for the fourth quarter of 2024 compared to a net loss of $25.7 million for the same period in 2023.

Adjusted EBITDA increase, attributing the success to strategic cost reductions, preferred payor strategy, and improved rates from government affairs efforts. He also emphasized the positive operating cash flow and free cash flow, which underscore the business’s ongoing strength.

As of December 28, 2024, Aveanna had a solid liquidity position with cash of $84.3 million and significant borrowing capacity under various facilities. The company has also hedged its interest rate exposure, providing further financial stability.

https://www.investing.com/news/stock-market-news/aveanna-healthcare-stock-soars-on-strong-q4-results-and-upbeat-2025-outlook-93CH-3927452

H.C. Wainwright maintains Buy on electroCore stock, $25 target

 On Thursday, H.C. Wainwright reiterated a Buy rating and a price target of $25.00 on electroCore Inc. (NASDAQ:ECOR), following the company’s fiscal year 2024 financial results. electroCore, which focuses on medical treatment through bioelectronic medicine, reported a significant year-over-year revenue increase and outlined its strategy for the upcoming year. According to InvestingPro data, the company’s market capitalization stands at $86.53 million, with analyst price targets ranging from $20 to $29, suggesting potential upside from the current $13 trading price.

The company plans to broaden its presence within existing sales channels and expand its product offerings through strategic partnerships. At the close of 2024, electroCore’s gammaCore, a non-invasive vagus nerve stimulator, was purchased by 170 Veterans Affairs (VA) facilities, up from 147 at the end of 2023. The company’s total revenues for 2024 reached $25.2 million, marking a 57% increase from the $16.0 million reported in 2023. InvestingPro analysis reveals impressive revenue growth of 74.1% in the last twelve months, with a healthy gross profit margin of 83.3%.

The fourth quarter of 2024 saw the company ending on a strong note, with total sales amounting to $7.0 million, an 8% quarter-over-quarter increase from $6.6 million in the third quarter. Sales through the VA/Department of Defense (DoD) channel remained the primary revenue driver, with $17.8 million in 2024 revenue, an 85% year-over-year growth from $9.6 million in 2023. However, the fourth quarter showed a slight 4.5% quarter-over-quarter decrease in this channel, from $4.8 million in the third quarter to $4.6 million.

Despite potential uncertainties in the VA/DoD channel sales due to possible reductions in supply chain staff within the VA system, H.C. Wainwright anticipates that recent transactions with NeuroMetrix (NASDAQ:NURO), Inc., and Spark Biomedical will help offset any negative impact. The firm conservatively projects electroCore’s total revenues for 2025 to be approximately $30 million and maintains its 12-month price target of $25 per diluted share. For deeper insights into electroCore’s financial health and growth prospects, investors can access the comprehensive Pro Research Report available on InvestingPro, which includes detailed analysis of the company’s fundamentals, valuation metrics, and growth potential.

https://in.investing.com/news/analyst-ratings/hc-wainwright-maintains-buy-on-electrocore-stock-25-target-93CH-4720527